Acetylcholinesterase inhibition by fused dihydroquinazoline compounds
摘要:
A new type of dihydroquinazoline-based inhibitor of acetylcholinesterase (AChE) is described. These compounds were designed to interact with the catalytic site of AChE in a manner similar to the known inhibitor tacrine, In a manner analogous to the potency enhancement obtained by addition of chlorine atoms to the tacrine molecule, a 3-chloro derivative of the parent hexahydroazepino[2,1-b]quinazoline structure was found to be about 8 times more potent as an AChE inhibitor than the unsubstituted compound.
One pot conversion of azido arenes to N-arylacetamides and N-arylformamides: synthesis of 1,4-benzodiazepine-2,5-diones and fused [2,1-b]quinazolinones
摘要:
Sodium iodide in acidic media has been employed for the synthesis of N-arylformamides and N-arylacetamides. The NaI/acetic acid reagent system has also been extended for the synthesis of 1,4-benzodiazepine-2,5-diones, pyrrolo[2,1-c][1,4]benzodiazepine-5,11-diones, and fused [2,1-b]quinazolinones. (C) 2004 Published by Elsevier Ltd.
A Polymer-Assisted Solution-Phase Strategy for the Synthesis of Fused [2,1-<i>b</i>]Quinazolinones and the Preparation of Optically Active Vasicinone
作者:Ahmed Kamal、V. Devaiah、N. Shankaraiah、K. Reddy
DOI:10.1055/s-2006-951482
日期:2006.9
An efficient preparation of fused [2,1-b]quinazolinones has been developed utilizing polymer-supported reagents. (±)-Vasicinone was converted into its dione by oxidation with poly (4-vinylpyridiniumdichromate). An efficient method has been developed for the synthesis of (d)- and (l)-vasicinone via asymmetric reduction of pyrrolo[2,l-b]quinazoline-3,9-dione by employing NaBH 4 /Me 3 SiCl as the reducing
[EN] QUINAZOLINE DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS
申请人:WARNER-LAMBERT COMPANY
公开号:WO1993003034A1
公开(公告)日:1993-02-18
(EN) A method of treating cognitive deficiencies is described by administering a quinazoline derivative of general formula (I) wherein A represents (IIa), (IIb), (IIc), (IId) or (IIe) in which n is 1-10, P is a bond or (CH2)m in which m is 0-10, and M is =O, =S, =NR, =CRR', (III); novel compounds of the above are also described as well as methods of manufacture and pharmaceutical compositions.(FR) L'invention décrit un procédé de traitement de déficiences cognitives au moyen de l'administration d'un dérivé de quinazoline représenté par la formule générale (I) dans laquelle A représente (IIa), (IIb), (IIc), (IId) ou (IIe) où n est 1-10, P représente une liaison ou (CH2)m où m est 0-10 et M représente =O, =S, =NR, =CRR', (III); l'invention décrit également de nouveaux composés comportant ledit dérivé, ainsi que des procédés de préparation et des compositions pharmaceutiques.